UniQure Soars as FDA Clears Huntington’s Therapy for US Filing
The article explicitly reports that UniQure shares surged after the FDA reversed its stance on the company’s Huntington’s disease gene therapy, allowing a US filing. This regulatory green light removes a key uncertainty and paves the way for potential approval, directly boosting the stock.
- ▲ FDA reversal on Huntington’s therapy AMT-130
- ▲ Clearance to file for US approval
- ▼ FDA may still not approve after filing
- ▼ Competing therapies could emerge
▼ Show FAQ (3) ▲ Hide FAQ
What does the FDA reversal mean for UniQure investors?
The FDA reversal signals a higher likelihood of AMT-130 reaching the US market, which could generate significant revenue for UniQure. The stock’s rally reflects increased probability of upside from the Huntington’s disease therapy.
Is UniQure’s stock a buy after this news?
The surge prices in some of the positive news, but further upside depends on the FDA’s review process and eventual approval. Investors should monitor upcoming filings and any additional FDA feedback.
Do other biotech companies benefit from this FDA reversal?
While the news is specific to UniQure, it may be seen as a positive signal for gene therapy developers facing regulatory challenges, though direct impact on competitors is limited.